RSL Revolutionary Labs Ltd, a pioneer in offering unique skincare formulations tailored specifically for oncology patients under their innovative brand, εὖSKIN®, is pleased to announce a strategic partnership with Smedo for the distribution of its revolutionary product line in Greece.

Dedicated to redefining skincare management, RSL has collaborated closely with esteemed scientists, dermatologists, and oncology specialists to develop εὖSKIN® – a groundbreaking range of dermaceutical solutions. These advanced formulas undergo rigorous validation, including extensive research and development, preclinical studies, and clinical data analysis, ensuring the provision of the best possible solutions for patients’ unique needs.

With over 15 natural ingredients and biomaterials, including molecularly engineered atelocollagen peptides, εὖSKIN® is designed to address the diverse challenges faced by oncology patients undergoing treatment. RSL’s ultimate goal is to improve the lives of those affected by cancer by providing effective and innovative skincare solutions.

Under the distribution agreement, Smedo will make the εὖSKIN® product line available through its e-shop, www.smedo.gr, providing Greek consumers with access to advanced dermaceutical solutions designed to prevent and care for sensitive affected skin, address damaged nails, and alleviate mucosal side effects.

"This partnership marks a significant milestone in our commercialization strategy,” said Dr. Marianna Prokopi – Demetriades, Founder of RSL Revolutionary Labs Ltd. “By teaming up with Smedo, we are enhancing our ability to serve oncology patients in Greece with innovative skincare solutions that prioritize both efficacy and patient comfort."

The distribution agreement aligns with RSL’s strategic goals of expanding its sales and distribution channels while reinforcing its commitment to innovation and growth in the dermaceutical industry. By leveraging Evomed’s extensive reach and expertise in the Greek market, RSL aims to establish the εὖSKIN® product line as the preferred dermocosmetic solution for cancer treatment-induced skin issues.

“We are delighted to be in partnership with RSL Revolutionary Labs for the launch of their ground-breaking εὖSKIN® products into the Greek market,” said Mr. Panos Xydias, CEO of Smedo. “This collaboration reinforces our commitment to providing high-quality healthcare products and solutions that offer a better way of life to patients fighting cancer by diversifying our product portfolio with specialised innovative skincare solutions tailored to the unique needs of oncology patients.”